Mer­ck nabs ap­proval for Keytru­da com­bo in kid­ney can­cer af­ter prov­ing it can ex­tend sur­vival

The FDA and out­side ex­perts have spent the last year talk­ing about can­cers where the ben­e­fits of Keytru­da and oth­er im­munother­a­pies are ques­tion­able, but in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER